Is CAR-NK The Natural Successor To CAR-Ts?
There is significant commercial potential on offer for the leading CAR-NK developers. While companies committed to continued CAR-T development will need to adapt and innovate in order to remain relevant, especially considering this disruptive new drug class.
You may also be interested in...
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.
The investment is the latest in Bayer’s series of moves into cell and gene therapy, amid growing industry interest in CAR-NKs.
Charting the development history and evolution of monoclonal antibodies as a therapeutic class reveals industry was slow to recognize their potential. The first 50 approvals took place over three decades, although the subsequent 50 were condensed into just five years as MAbs firmly revolutionized the treatment of a huge number of diseases. In Vivo asks whether RNA therapies, similarly underappreciated in the early days of development but now firmly in our collective conscience owing to their role in the pandemic response, are on the cusp of entering mainstream R&D?